A Novel Affinity Engineered Anti-CD47 Antibody With Improved Therapeutic Index That Preserves Erythrocytes and Normal Immune Cells

Therapeutic blockade of the CD47/SIRPα axis by small molecules or monoclonal antibodies (mAbs) is a proven strategy to enhance macrophages-mediated anti-tumor activity. However, this strategy has been hampered by elevated on-target toxicities and rapid clearance due to the extensive CD47 expression...

Descripción completa

Detalles Bibliográficos
Autores principales: Thaker, Youg R., Rivera, Ianne, Pedros, Christophe, Singh, Alok R., Rivero-Nava, Laura, Zhou, Heyue, Swanson, Barbara A., Kerwin, Lisa, Zhang, Yanliang, Gray, J. Dixon, Kaufmann, Gunnar F., Ji, Henry, Allen, Robert D., Bresson, Damien
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9161735/
https://www.ncbi.nlm.nih.gov/pubmed/35664753
http://dx.doi.org/10.3389/fonc.2022.884196

Ejemplares similares

Ejemplares similares